Overview
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Background
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.
Indication
Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients. Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications. Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired. Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.
Associated Conditions
- Acute Pulmonary Edema
- Ascites
- Body Fluid Retention
- Edema
- Hypertension
- Mild to Moderate Hypertension
- Chest congestion
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/04/23 | Phase 3 | Not yet recruiting | Stacy Johnson | ||
2025/03/27 | Phase 3 | Not yet recruiting | |||
2025/03/27 | Phase 1 | Recruiting | |||
2025/02/12 | Early Phase 1 | ENROLLING_BY_INVITATION | |||
2025/01/22 | Not Applicable | ENROLLING_BY_INVITATION | |||
2024/07/17 | Phase 1 | Completed | |||
2024/06/21 | Not Applicable | Recruiting | National Aeronautics and Space Administration (NASA) | ||
2024/06/04 | Phase 4 | Not yet recruiting | |||
2024/05/09 | Phase 3 | Not yet recruiting | |||
2024/03/22 | Phase 2 | Not yet recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Baxter Healthcare Corporation | 36000-064 | INTRAVENOUS | 10 mg in 1 mL | 10/27/2018 | |
A-S Medication Solutions | 50090-6219 | ORAL | 20 mg in 1 1 | 7/14/2017 | |
Physicians Total Care, Inc. | 54868-2299 | INTRAVENOUS | 10 mg in 1 mL | 3/1/2012 | |
State of Florida DOH Central Pharmacy | 53808-0367 | ORAL | 20 mg in 1 1 | 6/2/2010 | |
RedPharm Drug, Inc. | 67296-0691 | ORAL | 20 mg in 1 1 | 1/13/2021 | |
Bryant Ranch Prepack | 63629-1120 | ORAL | 80 mg in 1 1 | 7/30/2020 | |
NorthStar Rx LLC | 72603-133 | INTRAVENOUS | 10 mg in 1 mL | 12/27/2022 | |
A-S Medication Solutions | 50090-2560 | ORAL | 20 mg in 1 1 | 6/28/2018 | |
Major Pharmaceuticals | 0904-7178 | ORAL | 40 mg in 1 1 | 12/30/2021 | |
Aphena Pharma Solutions - Tennessee, LLC | 71610-284 | ORAL | 20 mg in 1 1 | 5/30/2019 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
APO-FUROSEMIDE TABLET 40 mg | SIN00088P | TABLET | 40 mg | 3/14/1988 | |
FUROSEMIDE-AFT SOLUTION FOR INJECTION 20MG/2ML | SIN16784P | INJECTION, SOLUTION | 20mg/2ml | 5/16/2023 | |
FUROSEMIDE-BAXTER SOLUTION FOR INJECTION 20 MG/2 ML | SIN15366P | INJECTION, SOLUTION | 20 mg/2 mL | 11/23/2017 | |
RASITOL TABLET 40MG | SIN14074P | TABLET | 40mg | 1/9/2012 | |
DIRINE INJECTION 20 mg/2 ml | ATLANTIC LABORATORIES CORPN LTD | SIN00239P | INJECTION | 20 mg/2 ml | 4/5/1988 |
FUROSEMIDE-BAXTER SOLUTION FOR INJECTION 50 MG/5 ML | SIN15365P | INJECTION, SOLUTION | 50 mg/5 mL | 11/23/2017 | |
FUSETIC SOLUTION FOR INJECTION 20MG/2ML | SIN16712P | INJECTION, SOLUTION | 20mg/2ml | 2/23/2023 | |
LASIX TABLET 40 mg | SIN00199P | TABLET | 40.00 mg | 3/28/1988 | |
FUROSEMIDE FRESENIUS KABI SOLUTION FOR INJECTION 20MG/2ML | SIN15131P | INJECTION, SOLUTION | 20mg/2ml | 12/7/2016 | |
FURMIDE TABLETS 40 mg | SIN00064P | TABLET | 40.00 mg | 2/24/1988 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Furosemide Tablets | 国药准字H62020258 | 化学药品 | 片剂 | 4/10/2020 | |
Furosemide Tablets | 国药准字H51022778 | 化学药品 | 片剂 | 8/5/2020 | |
Furosemide for Injection | 国药准字H20070276 | 化学药品 | 注射剂 | 3/28/2022 | |
Furosemide for Injection | 国药准字H20060659 | 化学药品 | 注射剂 | 7/3/2020 | |
Furosemide for Injection | 国药准字H20051479 | 化学药品 | 注射剂 | 12/11/2020 | |
Furosemide for Injection | 国药准字H20051478 | 化学药品 | 注射剂 | 12/11/2020 | |
Furosemide for Injection | 国药准字H20051116 | 化学药品 | 注射剂 | 7/3/2020 | |
Furosemide Tablets | 国药准字H12020163 | 化学药品 | 片剂 | 9/25/2020 | |
Furosemide Tablets | 国药准字H44021490 | 化学药品 | 片剂 | 3/30/2020 | |
Furosemide Tablets | 国药准字H44022268 | 化学药品 | 片剂 | 11/27/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
FUROSEMIDE TABLETS BP 40MG | N/A | N/A | N/A | 10/5/2020 | |
FUROSEMIDE-HAMELN SOLUTION FOR INJECTION 20MG/2ML | N/A | mekim ltd | N/A | N/A | 5/27/2025 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
IP Furosemide furosemide (frusemide) 40 mg tablet bottle | 412881 | Medicine | A | 2/5/2024 | |
I-Furosemide furosemide (frusemide) 20 mg tablet bottle | 412876 | Medicine | A | 2/5/2024 | |
UREX furosemide (frusemide) 40 mg tablet blister pack | 34494 | Medicine | A | 1/17/1992 | |
FUROSEMIDE-BAXTER furosemide (frusemide) 20 mg/2 mL solution for injection ampoule | 148003 | Medicine | A | 4/3/2009 | |
Furosemide-WGR furosemide 40 mg tablet bottle | 186522 | Medicine | A | 6/28/2012 | |
IP Furosemide furosemide (frusemide) 20 mg tablet bottle | 412877 | Medicine | A | 2/5/2024 | |
FRUSIPCA furosemide (frusemide) 20 mg tablet bottle | 412874 | Medicine | A | 2/5/2024 | |
Furosemide-WGR furosemide 20 mg tablet bottle | 186524 | Medicine | A | 6/28/2012 | |
FRUSEMIX furosemide 40 mg tablet bottle | 186521 | Medicine | A | 6/28/2012 | |
LASIX furosemide 20mg/2mL injection ampoule | 12404 | Medicine | A | 8/1/1991 |